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Varicella in Pregnancy: Five Priorities
for Clinicians
Editorial
Acute varicella (chicken pox) is one of the most highly contagious viral illnesses.
The infection occurs commonly in childhood, and approximately 95% of individ-
uals are immune by the time they reach childbearing age. Varicella occurs in fewer
than 1:1,000 pregnancies each year. Although it is a relatively mild illness in
children, varicella may cause severe complications in pregnant women and their
fetuses. Accordingly, physicians and nurses who provide obstetric care must be
aware of the following 5 priorities.
First, at the time of the patient’s first prenatal appointment, she should be
questioned about a history of varicella. If she is certain she had chicken pox, she
should be reassured that second infections are extremely unlikely and that she need
not fear accidental exposure to a person with varicella. If the patient is uncertain
about her history and a family member is unable to verify that infection occurred, a
serologic test to determine immune status should be performed.
2 This test is
particularly important in women who have frequent occupational exposure to
children with viral illnesses, e.g., school teachers, day care workers, and health
care workers. The appropriate serologic test for determining immune status is
measurement ofIgG antibody by an enzyme-linked immunosorbent assay (ELISA)
or the fluorescent antibody test for membrane antigen (FAMA). Approximately
80% of patients with uncertain histories will, in fact, have evidence of immunity,
and they can be reassured that they are not at risk during the present pregnancy.
Susceptible women must be specifically counseled to avoid exposure to other
individuals who may have varicella.
The second priority is to promptly and correctly evaluate the obstetric patient
who has been exposed to an individual with acute varicella and whose serologic
status is either unknown or negative. In the former case a serologic test should
immediately be performed. Laboratory personnel must be informed of the need for
completion of the test within 24--48 h. If the patient is seronegative or if the
laboratory test cannot be completed promptly, the patient should be offered vari-
cella-zoster immune globulin (VZIG). This preparation contains high titer of
antibody to the varicella-zoster virus, and, if it is given within 4 days of exposure,
is of benefit in preventing or attenuating subsequent illness. The appropriate dose
of VZIG is vial (125 units) per 10 kg body weight, administered intramuscu-
larly, up to a maximum of 5 vials (625 units).
3 The approximate cost of VZIG is
$4OO-$6OO.
The third priority is to treat appropriately patients who present for care more
than 4 days after exposure or who become infected despite receiving VZIG. These
patients should be counseled about the major complications of varicella: dissemi-
nated infection, which is extremely uncommon in immunocompetent patients;
encephalitis, which occurs in <1% of patients; and pneumonia, which may occur
in 20-50% of patients. In reports published prior to the availability of effective
antiviral chemotherapy, the mortality in pregnant women with varicella pneumo-
nia was as high as 40%.
4 Patients should be instructed to report immediately if
signs of severe systemic illness develop. If evaluation confirms the presence of aVARICELLA IN PREGNANCY DUFF
serious complication, the patient should be hospitalized and treated with intrave-
nous acyclovir, 10-15 mg/kg or 500 mg/m
2 3 times a day for approximately 7
days.
4 Consultation with specialists in infectious diseases, pulmonology, and criti-
cal care may be indicated.
The fourth priority is to evaluate exposed fetuses for possible congenital vari-
cella infection. Recent reports have shown that the incidence of anatomic anomalies
related to maternal varicella infection ranges from 0 to 9%.
1,s Serologic evidence
of congenital infection may be present in up to 25% of exposed neonates. Several
diagnostic testshave been proposed for identification of affected fetuses, including
amniocentesis, chorionic villus sampling (CVS), cordocentesis, and ultrasound. 6’7
Identification of virus, viral antigen, or antibody in amniotic fluid, placental
tissue, or fetal blood confirms that infection has occurred but does not indicate that
the fetus has been seriously injured. The best test for identifying the fetus with
anomalies is ultrasound. Ultrasound findings suggestive of congenital varicella
include, but are not limited to, polyhydramnios, hydrops, ventriculomegaly,
microcephaly, cardiac anomalies, limb abnormalities, intrauterine growth retarda-
tion, and dystrophic calcifications in multiple organs, especially the liver.
7 Moth-
ers with affected infants may be offered pregnancy termination if the gestational
age is appropriate.
The fifth priority is to provide appropriate care to the mother and neonate when
the former is acutely infected at the time of delivery. When infection occurs during
the period 5 days before to 2 days after delivery, the fetus may be exposed to an
intense viremia without benefit of transplacental transfer of maternal antibody. Up
to 40% of these infants develop neonatal varicella, and the mortality in untreated
infants approaches 20%.
8 Accordingly, the pediatrician who will be caring for the
infant must be notified promptly that an acutely infected mother is about to deliver.
Immediately following delivery, the infant should receive VZIG at the direction of
the pediatrician. In addition, mother and infant should be separated at least until
neonatal assessment has been completed and immunoprophylaxis has been admin-
istered.
In summary, varicella in pregnancy is a rare, but potentially fatal, disorder for
both mother and fetus. The immune status of patients should be determined early
in pregnancy. Susceptible patients are candidates for immunoprophylaxis if expo-
sure occurs. Infected patients should be monitored for serious complications, and
their fetuses should be assessed for congenital infection with ultrasound examina-
tion. Infants at risk for neonatal varicella are also candidates for immunoprophy-
laxis with VZIG.
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